235 related articles for article (PubMed ID: 18346918)
21. Kaiso is a key regulator of spleen germinal center formation by repressing Bcl6 expression in splenocytes.
Koh DI; Yoon JH; Kim MK; An H; Kim MY; Hur MW
Biochem Biophys Res Commun; 2013 Dec; 442(3-4):177-82. PubMed ID: 24269670
[TBL] [Abstract][Full Text] [Related]
22. Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells.
Phan RT; Saito M; Kitagawa Y; Means AR; Dalla-Favera R
Nat Immunol; 2007 Oct; 8(10):1132-9. PubMed ID: 17828269
[TBL] [Abstract][Full Text] [Related]
23. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
24. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells.
Polo JM; Ci W; Licht JD; Melnick A
Blood; 2008 Aug; 112(3):644-51. PubMed ID: 18487509
[TBL] [Abstract][Full Text] [Related]
25. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.
Béguelin W; Teater M; Gearhart MD; Calvo Fernández MT; Goldstein RL; Cárdenas MG; Hatzi K; Rosen M; Shen H; Corcoran CM; Hamline MY; Gascoyne RD; Levine RL; Abdel-Wahab O; Licht JD; Shaknovich R; Elemento O; Bardwell VJ; Melnick AM
Cancer Cell; 2016 Aug; 30(2):197-213. PubMed ID: 27505670
[TBL] [Abstract][Full Text] [Related]
26. PU.1 can recruit BCL6 to DNA to repress gene expression in germinal center B cells.
Wei F; Zaprazna K; Wang J; Atchison ML
Mol Cell Biol; 2009 Sep; 29(17):4612-22. PubMed ID: 19564417
[TBL] [Abstract][Full Text] [Related]
27. CD137L and CD4 T cells limit BCL6-expressing pre-germinal center B cell expansion and BCL6-driven B cell malignancy.
Ding Z; Quast I; Yan F; Liao Y; Pitt C; O-Donnell K; Robinson MJ; Shi W; Kallies A; Zotos D; Tarlinton DM
Immunol Cell Biol; 2022 Oct; 100(9):705-717. PubMed ID: 35916066
[TBL] [Abstract][Full Text] [Related]
28. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
[TBL] [Abstract][Full Text] [Related]
29. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
30. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
[TBL] [Abstract][Full Text] [Related]
31. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
[TBL] [Abstract][Full Text] [Related]
32. BCL6 promoter interacts with far upstream sequences with greatly enhanced activating histone modifications in germinal center B cells.
Ramachandrareddy H; Bouska A; Shen Y; Ji M; Rizzino A; Chan WC; McKeithan TW
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11930-5. PubMed ID: 20547840
[TBL] [Abstract][Full Text] [Related]
33. AID-associated DNA repair pathways regulate malignant transformation in a murine model of BCL6-driven diffuse large B-cell lymphoma.
Gu X; Booth CJ; Liu Z; Strout MP
Blood; 2016 Jan; 127(1):102-12. PubMed ID: 26385350
[TBL] [Abstract][Full Text] [Related]
34. Roles of BCL6 in normal and transformed germinal center B cells.
Basso K; Dalla-Favera R
Immunol Rev; 2012 May; 247(1):172-83. PubMed ID: 22500840
[TBL] [Abstract][Full Text] [Related]
35. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
[TBL] [Abstract][Full Text] [Related]
36. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
[TBL] [Abstract][Full Text] [Related]
37. Cutting edge: T follicular helper cell differentiation is defective in the absence of Bcl6 BTB repressor domain function.
Nance JP; Bélanger S; Johnston RJ; Takemori T; Crotty S
J Immunol; 2015 Jun; 194(12):5599-603. PubMed ID: 25957170
[TBL] [Abstract][Full Text] [Related]
38. The Amount of BCL6 in B Cells Shortly after Antigen Engagement Determines Their Representation in Subsequent Germinal Centers.
Robinson MJ; Ding Z; Pitt C; Brodie EJ; Quast I; Tarlinton DM; Zotos D
Cell Rep; 2020 Feb; 30(5):1530-1541.e4. PubMed ID: 32023467
[TBL] [Abstract][Full Text] [Related]
39. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
[TBL] [Abstract][Full Text] [Related]
40. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.
Boccellato F; Anastasiadou E; Rosato P; Kempkes B; Frati L; Faggioni A; Trivedi P
J Virol; 2007 Mar; 81(5):2274-82. PubMed ID: 17151114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
